Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 26 Jun, 26 | JNJ | Buy | USD 244.88 | USD 258.0 | USD 270.0 | 3 days | Closed |
5.36%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Oncology Sales Growth: Q1FY26 Oncology sales of USD 6.97 billion vs USD 5.68 billion in Q1FY25.
MedTech Business Growth: Q1FY26 MedTech sales of USD 8.64 billion vs USD 8.02 billion in Q1FY25
Lower Diluted EPS: Q1FY26 diluted EPS of USD 2.14 vs USD 4.54 in Q1FY25
Decline in Net Earnings: Q1FY26 net earnings of USD 5.24 billion vs USD 11.00 billion in Q1FY25
The company faces risks from biosimilar competition for key products, patent expirations, pricing pressures, regulatory uncertainties, litigation exposure, and execution risks associated with commercializing new therapies and advancing its pipeline
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 244.88 | 220.0 | 258.0 | 270.0 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Revenue Growth Across Core Businesses: Johnson & Johnson delivered a solid start to Q1FY26, with reported sales increasing 9.9% YoY to USD 24.1 billion, supported by 6.4% operational growth. Growth was driven by broad-based strength across Innovative Medicine and MedTech, reflecting sustained demand, commercial execution, and innovation. The company also raised its FY26 revenue and earnings guidance, reinforcing confidence in its growth outlook.
Innovative Medicine Driven by High-Growth Portfolio: Innovative Medicine sales increased 11.2% YoY to USD 15.4 billion, with operational growth of 7.4%. Strong momentum from DARZALEX, CARVYKTI, RYBREVANT/LAZCLUZE, TREMFYA, SPRAVATO, and CAPLYTA more than offset biosimilar pressure on STELARA. Regulatory approvals for ICOTYDE and expanded indications for TECVAYLI plus DARZALEX further strengthened the long-term growth pipeline.
MedTech Innovation Supports Sustainable Expansion: MedTech revenue increased 7.7% YoY to USD 8.6 billion, driven by operational growth of 4.6%. Cardiovascular, Surgery, Vision, and Orthopaedics delivered broad-based growth, supported by strong adoption of electrophysiology products, Abiomed, Shockwave, and trauma solutions. New product launches, including VARIPULSE Pro and TECNIS PureSee, continue to strengthen the company's competitive positioning.
Robust Pipeline and Capital Allocation Enhance Long-Term Visibility: The company continued advancing multiple regulatory approvals, product launches, and late-stage pipeline programs across oncology, immunology, neuroscience, cardiovascular, surgery, and vision. Johnson & Johnson also announced more than USD 1 billion of investment in a new cell therapy manufacturing facility while maintaining disciplined capital allocation through R&D investment, dividends, and increased FY26 guidance.
Considering recent key business, financial updates, current trading levels, and key business risks, a ‘Buy’ recommendation has been given to Johnson & Johnson (NYSE: JNJ) at the closing market price of USD 244.88, as on 25 June,2026
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson |
-4.22 1.67% | 248.82 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| LLY Eli Lilly and Company |
-32.21 2.73% | 1146.90 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| ABBV AbbVie Inc |
-1.11 0.44% | 253.38 | 86.32 | 14.33 | 5.89 | 50.46 | 7.04 | 24.44 |
| AZN AstraZeneca PLC |
-4.38 2.59% | 164.52 | 30.69 | 19.23 | 5.30 | 6.45 | 5.72 | 17.23 |
| MRK Merck & Company Inc |
-3.1 2.43% | 124.40 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Data Powered by EOD Historical Data (“EODHD”).
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels as on June 26, 2026. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned has been achieved and is subject to the factors discussed above.
Note 4: StockNextt reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2026 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
Australia